Press release from Companies
Published: 2020-12-18 17:17:41
Dear shareholder in Scandion Oncology, dear subscriber to Scandion Oncology News, At the cusp of the year 2020, and with almost 90 days for me as CEO, we can look back on a year in which Scandion Oncology entered two programs in clinical development with our lead candidate SCO-101 and we have thereby established the cornerstones in the strategic direction to become The Cancer Drug Resistance Company or said in other words: the company developing the first drugs that can revert resistance towards chemotherapy.
As you are aware, this week, Scandion Oncology announced the results of the Rights Issue and the raising proceeds of approximately SEK 236 million. On that note, I would like to extend a very warm welcome to all new shareholders, we thank both you and existing shareholders for the commitment to our company. Hereby, the direction is set for the future we aspire for, to transform from a clinical stage biotech to a company with validating data from clinical trials and with a strategic long-term plan of how to become a significant first mover in cancer drug resistance. Thus, Scandion Oncology is placed at the best possible position when entering discussions of lucrative partner- and license agreements. I look forward to sharing the next elements of our strategy in connection with the next reports from the company as well as keeping you updated on our progress as we achieve our milestones. We will report our year-end and Q4 figures on 18 Feb 2021. Other events and newly published articles to look out for: I personally, and with me the whole team at Scandion Oncology, invest our efforts and experience every day because we see a need to make a difference in this very important area of medicine. On behalf of the team at Scandion Oncology, I wish you the best for the season and the new year! Stay tuned for more, Bo Rode Hansen, PhD MBA Scandion Oncology A/S
President & CEO
Fruebjergvej 3
DK-2100 Copenhagen
T: +45 38 10 20 17
E: info@scandiononcology.com
